Urinary Incontinence Market Report 2026

The urinary incontinence market size has grown strongly in recent years. It will grow from $13.33 billion in 2025 to $14.2 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to increasing aging population, rising prevalence of obesity-related conditions, higher incidence of childbirth-related pelvic disorders, improved access to diagnostic healthcare services, growing awareness of urinary health disorders.

The urinary incontinence market size is expected to see strong growth in the next few years. It will grow to $18.84 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to expansion of personalized treatment approaches, rising adoption of digital health monitoring tools, growing demand for non-surgical therapies, increasing focus on preventive urological care, advancements in incontinence treatment devices. Major trends in the forecast period include increasing adoption of advanced diagnostic methods, rising demand for minimally invasive treatment options, growing focus on pelvic floor rehabilitation therapies, expansion of home-based incontinence management solutions, enhanced awareness of urinary health conditions.

The rising prevalence of urological disorders is expected to drive the growth of the urinary incontinence market going forward. Urological disorders encompass medical conditions affecting the urinary system and male reproductive organs, including the kidneys, bladder, ureters, urethra, prostate, and testes. The increase in these disorders is fueled by aging populations and lifestyle-related health changes, which contribute to a growing disease burden. The urinary incontinence market addresses this trend by providing diagnostic tools, therapeutic products, and advanced treatment solutions that meet rising patient needs. For example, in January 2023, the American Cancer Society, a US-based voluntary cancer awareness organization, reported an estimated 82,290 urinary bladder cancer cases in 2023, indicating an increase compared to previous years as the disease burden continues to grow. Therefore, the rising prevalence of urological disorders is fueling the growth of the urinary incontinence market.

Key companies in the urinary incontinence market are focusing on developing innovative solutions, such as smart, automated artificial urinary sphincters and advanced minimally invasive devices, to improve treatment outcomes and patient quality of life. These technologies are designed to enhance bladder control by automatically regulating urine flow while offering less invasive and more comfortable treatment options. For instance, in July 2023, UroMems SAS, a France-based biotechnology company, successfully implanted the UroActive smart, automated artificial urinary sphincter (AUS) in a female patient to treat stress urinary incontinence (SUI). The UroActive device, powered by a myoelectrical mechanical system (MEMS), addresses the unmet need for a definitive SUI treatment in women. The procedure was performed with robotic assistance at La Pitié-Salpêtrière University Hospital in Paris, with regulatory approval from the French equivalent of the FDA. The device’s adjustability, smart functionality, and minimally invasive approach are aimed at improving patient quality of life.

In September 2023, Amber Therapeutics, a UK-based medtech company, acquired Bioinduction Limited for an undisclosed amount. Through this acquisition, Amber gained the Picostim DyNeuMo neuromodulation therapy platform, which delivers closed-loop therapy specifically for mixed urinary incontinence, marketed as Amber-UI. Bioinduction Limited is a UK-based medical device company specializing in neuromodulation technologies for urinary incontinence.

Major companies operating in the urinary incontinence market are Teleflex Incorporated, Ethicon Inc., Laborie Medical Technologies Corp., NeoTract Inc., Promedon GmbH, Caldera Medical Inc, Cook Medical Inc, Cook Group Inc, ConvaTec Group PLC, Boston Scientific Corporation, Coloplast A/S, B Braun Melsungen AG, Medtronic plc, Hollister Incorporated, Becton Dickinson and Company, A.M.I. GmbH, Atlantic Therapeutics Group Ltd, InControl Medical, Zephyr Surgical Implants.

North America was the largest region in the urinary incontinence market in 2025. The regions covered in the urinary incontinence market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the urinary incontinence market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the urinary incontinence market by increasing costs of imported medical devices, diagnostic equipment, pharmaceutical ingredients, and disposable care products used across hospitals, clinics, and homecare settings. Healthcare providers in North America and Europe are most affected due to dependence on imported urology devices and drug components, while Asia-Pacific faces pricing pressure on export-oriented manufacturing. These tariffs are increasing treatment costs and procurement budgets for healthcare facilities. However, they are also encouraging local manufacturing of continence products, regional pharmaceutical sourcing, and domestic innovation in cost-effective incontinence management solutions.

The urinary incontinence market research report is one of a series of new reports that provides urinary incontinence market statistics, including urinary incontinence industry global market size, regional shares, competitors with a urinary incontinence market share, detailed urinary incontinence market segments, market trends and opportunities, and any further data you may need to thrive in the urinary incontinence industry. This urinary incontinence market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Urinary incontinence is a medical condition characterized by the involuntary loss of urine, ranging from occasional leaks to a complete inability to control urination. It can be caused by weakened pelvic floor muscles, hormonal changes, obesity, neurological conditions, urinary tract infections, medications, and pregnancy.

The main types of urinary incontinence include urge incontinence, stress incontinence, overflow incontinence, and functional incontinence. Urge incontinence, also called overactive bladder, involves a sudden and strong urge to urinate that is difficult to control. It is managed through medications that relax and regulate bladder muscles, behavioral techniques such as bladder training, and lifestyle modifications. Treatments, including medications, devices, and others, can be administered orally, parenterally, or via other routes. Diagnostic and treatment tools and services, such as physical exams, pad tests, urodynamic testing, cystoscopy, stress tests, ultrasound, and urine analysis, are provided by end-users including hospitals, specialty clinics, homecare providers, and others.

The urinary incontinence market includes revenues earned by entities by providing medical diagnosis and evaluation, medication and surgical interventions, pelvic floor muscle training and physical therapy, behavioral therapies and bladder training and counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The urinary incontinence market also includes sales of electrical stimulation devices, foley catheters, antimicrobial foley catheters and urethral bulking agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.